Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study

详细信息    查看全文

• 作者：Eduardo Martínez de Due?as (1)
  Ana Lluch Hernández (2)
  ángel Guerrero Zotano (3)
  Ramón María Pérez Carrión (4)
  José Ignacio Chacón López-Mu?iz (5)
  Silvia Antolín Novoa (6)
  ángela López Rodríguez (1)
  José Alejandro Pérez Fidalgo (2)
  Jaime Ferrer Lozano (2)
  Octavio Burgués Gasión (2)
  Eva Carrasco Carrascal (7)
  Andrés Hernando Capilla (7)
  Isabel Blancas López-Barajas (8)
  Montserrat Mu?oz Mateu (9)
  María Helena López de Ceballos Reyna (10)
  Amparo Oltra Ferrando (11)
  Noelia Martínez Ja?ez (12)
  Vicente Cara?ana Ballerini (13)
  Antonio Antón Torres (14)
  Gustavo Catalán (15)
  José ángel García Sáenz (16)
  Salomón Menjón (17)
  Ana María González-Angulo (18)
  
• 关键词：Breast neoplasm ; Conversion ; Hormone receptors ; HER2 ; Tumor markers
• 刊名：Breast Cancer Research and Treatment
• 出版年：2014
• 出版时间：February 2014
• 年：2014
• 卷：143
• 期：3
• 页码：507-515
• 全文大小：302 KB
• 作者单位：Eduardo Martínez de Due?as (1)
  Ana Lluch Hernández (2)
  ángel Guerrero Zotano (3)
  Ramón María Pérez Carrión (4)
  José Ignacio Chacón López-Mu?iz (5)
  Silvia Antolín Novoa (6)
  ángela López Rodríguez (1)
  José Alejandro Pérez Fidalgo (2)
  Jaime Ferrer Lozano (2)
  Octavio Burgués Gasión (2)
  Eva Carrasco Carrascal (7)
  Andrés Hernando Capilla (7)
  Isabel Blancas López-Barajas (8)
  Montserrat Mu?oz Mateu (9)
  María Helena López de Ceballos Reyna (10)
  Amparo Oltra Ferrando (11)
  Noelia Martínez Ja?ez (12)
  Vicente Cara?ana Ballerini (13)
  Antonio Antón Torres (14)
  Gustavo Catalán (15)
  José ángel García Sáenz (16)
  Salomón Menjón (17)
  Ana María González-Angulo (18)
  
  1. Hospital Provincial de Castellón, Avda. Doctor Clara, 19, 12002, Castellón de la Plana, Spain
  2. Hematology and Medical Oncology Department, INCLIVA Biomedical Research Institute, Hospital Clínico de Valencia, Avda. Blasco Ibá?ez, 17, 46011, Valencia, Spain
  3. Instituto Valenciano de Oncología, c/Estrella, 3, 46007, Valencia, Spain
  4. Clínica Quirón, c/Juan Bravo, 39, 28006, Madrid, Spain
  5. Hospital Virgen de la Salud, Avda. de Barber, 30, 45071, Toledo, Spain
  6. Complejo Hospitalario Universitario A Coru?a, c/As Xubias, 84, 15006, A Coru?a, Spain
  7. GEICAM (Grupo Espa?ol de Investigación en Cáncer de Mama), Avda. de los Pirineos, 7. Oficina 1-4, 28700, San Sebastián de los Reyes, Madrid, Spain
  8. Hospital Clínico San Cecilio, Avda. Doctor Oloriz, 16, 18012, Granada, Spain
  9. Hospital Clínic i Provincial, c/Carrer Villarroel, 170, 08036, Barcelona, Spain
  10. Hospital San Pedro de Alcántara, Avda. Pablo Naranjo, s/n, 10003, Cáceres, Spain
  11. Hospital Virgen de los Lirios, c/Caramanxel, s/n, 03804, Alcoy, Alicante, Spain
  12. Hospital Universitario Ramón y Cajal, c/San Modesto, 50, 28034, Madrid, Spain
  13. Hospital Arnau de Vilanova, c/San Clemente, 12, 46015, Valencia, Spain
  14. Hospital Miguel Servet, Po/Isabel la Católica, 1-3, 50009, Zaragoza, Spain
  15. Hospital Son Llàtzer, Ctra. Manacor, Km. 4,0, 07198, Palma de Mallorca, Spain
  16. Hospital Clínico San Carlos, c/Profesor Martín Lagos, s/n, 28040, Madrid, Spain
  17. Hospital Universitario Virgen de las Nieves, Avda. de las Fuerzas Armadas, 2, 18014, Granada, Spain
  18. The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA
  
• ISSN：1573-7217

文摘

The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone receptor (PR) between primary tumors and metastatic lesions in advanced breast cancer. Patients with suspected diagnosis of locally recurrent or metastatic breast cancer, either at first relapse or after successive disease progressions, who had an appropriately preserved sample from a primary tumor and were scheduled for a biopsy of the recurrent lesion, were included. Blinded determinations of receptor status on paired samples were performed by immunohistochemistry and fluorescence in situ hybridization at a central laboratory and compared with those performed locally. Overall, 196 patients were included and 184 patients were considered evaluable. Reasons for non-evaluability included the inability to perform biopsy (n?=?4) or biopsy results showing normal tissue (n?=?3), benign disease (n?=?3) or a second neoplasia (n?=?2). Conversion rates determined at local level were higher than those determined centrally (HER2: 16 vs. 3?%, ER: 21 vs. 13?%, PR: 35 vs. 28?%, respectively). There was substantial agreement regarding the expression of HER2 in primary tumors and metastases, and ER at metastases, between local and central laboratories. PR at any site and ER at primary site showed moderate agreement. Oncologists altered their treatment plans in 31?% of patients whose tumor subtype had changed. These results reinforce the recommendation for performing confirmatory biopsies of metastases, not only to avoid misdiagnosis of breast cancer relapse, but also to optimize treatment (clinicaltrials.gov identifier: NCT01377363).